Wiley appoints Dr. Karen N. Madden to Board

By Tamara Parker • Wednesday, March 05 15:14 • Permanent Link

Wiley, a leading publisher and research company, has appointed Dr. Karen N. Madden, Ph.D., as a new member of its board of directors. Dr. Madden currently serves as the Senior Vice President and Chief Technology Officer at MilliporeSigma, a life science business of Merck KGaA, Darmstadt, Germany. She is responsible for shaping the technology roadmap and long-term R&D strategy, overseeing the life science innovation board, and providing overall leadership to the more than $9 billion life science business.

Dr. Madden's appointment brings a wealth of experience and expertise in science, technology, and innovation to Wiley's board. Her strategic vision and extensive knowledge in driving innovation across the research and development process will be invaluable as Wiley continues its transformation to deliver trusted content and services.

Prior to her role at MilliporeSigma, Dr. Madden served as the Senior Vice President and Chief Innovation Officer at PerkinElmer, where she was responsible for driving innovation across the company's businesses and end markets.

With a Ph.D. from Rutgers University and a background in chemistry with a focus in molecular biology, biochemistry, and biophysics, Dr. Madden's appointment aligns with Wiley's commitment to advancing knowledge and innovation. Her connection to the global research community and her expertise in science and technology make her a valuable addition to Wiley's board of directors.

Wiley's President & CEO, Matthew Kissner, expressed his confidence in Dr. Madden's appointment, highlighting her exceptional experience in science, technology, and innovation. Jesse Wiley, Board Chair, also expressed enthusiasm about Dr. Madden's appointment, emphasizing her alignment with the company's commitment to advancing knowledge.

Dr. Madden's appointment marks an important step for Wiley as it continues to innovate and grow, leveraging authoritative content and data to benefit society and the global knowledge landscape. The market has reacted to these announcements by moving the company's shares -0.1% to a price of $37.94. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.